Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Clinical Trials

47 clinical trials for Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia — RECRUITING · PHASE1
• 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome — RECRUITING · PHASE1
• Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy — RECRUITING · PHASE1
• Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome — COMPLETED · PHASE2
• Hu8F4 in Treating Patients With Advanced Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission — COMPLETED · PHASE3
• Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent — TERMINATED · PHASE2
• CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia — COMPLETED · PHASE2
• Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation — ACTIVE_NOT_RECRUITING · PHASE2
• Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia — COMPLETED · PHASE1
• Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) — NOT_YET_RECRUITING · PHASE2
• Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome — TERMINATED · PHASE2
• CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old — ACTIVE_NOT_RECRUITING · PHASE2
• Veliparib and Temozolomide in Treating Patients With Acute Leukemia — COMPLETED · PHASE1
• Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia — COMPLETED · PHASE2
• Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia — COMPLETED · PHASE2
• Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome — COMPLETED · PHASE1
• Nivolumab in AML in Remission at High Risk for Relapse — COMPLETED · PHASE2
• Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia — COMPLETED · PHASE1
• 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia — COMPLETED · PHASE1
• Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies — COMPLETED · PHASE1
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma — COMPLETED · PHASE2
• Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia — COMPLETED · PHASE2
• Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia — COMPLETED · PHASE2
• Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies — COMPLETED · PHASE1
• Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome — TERMINATED · PHASE1
• EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia — TERMINATED · PHASE1
• Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia — TERMINATED · PHASE2
• Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation — WITHDRAWN · PHASE2
• Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia — TERMINATED · PHASE1
• Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant — TERMINATED · PHASE1
• Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia — COMPLETED · PHASE2
• Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia — TERMINATED · PHASE2
• Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission — COMPLETED · PHASE2
• Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia — COMPLETED · PHASE1
• Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia — COMPLETED · PHASE2
• Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia — TERMINATED · PHASE1
• Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia — COMPLETED · PHASE1

Refine this search